Document is current

Any future updates will be listed below

Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer

Crossref DOI link: https://doi.org/10.1038/s41419-020-03208-z

Published Online: 2020-11-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark